AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02269553 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Hard TMJD Splint
Description: The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch.
Study NCT02353702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sniff test
Description: Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo
Study NCT02353702 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sniff test
Description: Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo
Study NCT02353702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion of Ropivacaine during 48 hours
Description: 20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml) during 48 hours of Ropivacaine.~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour, during 48 hours of NaCl 0.9 %.
Study NCT02353702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous parietal infusion with parietal catheter
Description: Continuous parietal infiltration of Ropivacaine or placebo
Study NCT02353702 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous parietal infusion with parietal catheter
Description: Continuous parietal infiltration of Ropivacaine or placebo
Study NCT02353702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Infusion of placebo during 48 hours
Study NCT02353702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl
Study NCT02353702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Study NCT00281099 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD (Implantable Cardioverter Defibrillator)
Description: VVI 40 vs. MVP
Study NCT03216343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: CS2164
Study NCT01016119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folrex
Description: Folrex cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
Study NCT01016119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
Study NCT02553551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given.
Study NCT02553551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given.
Study NCT01996696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg PO TID x 30-36 months
Study NCT01996696 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo TID x 30-36 months
Study NCT02644213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protocol of using CAREN and MOTEK systems
Description: The subjects will perform randomly 3 experimental days (at least weak between one to another):~* simulated road march using a virtual reality environment without additional load~* simulated road march using a virtual reality environment which combines cognitive load during the road march. Cognitive tasks for example: navigation, identification and remembering cars/aircraft.~* without physical or cognitive load (without march, waiting between performance evaluations) as control.
Study NCT02248441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily ischemic conditioning treatment
Description: RIC stimulus will be conducted as 4 x 5 minutes upper arm ischemia achieved by inflation of a blood pressure cuff to 200 mmHg and 5 minutes reperfusion between inflations. The procedure will be performed using the AutoRICTM (CellAegis Devices Inc., Toronto, Ontario, Canada).
Study NCT06660641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TaurolockTMHep100
Description: 1.35% taurolidine containing catheter losk solution
Study NCT01489488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: Single oral dose of 2.4 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 16 mL) under fed conditions
Study NCT01489488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: Single oral dose of 0.3 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 2 mL) under fasting conditions
Study NCT01489488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: Single oral dose of 0.15 mg riociguat as pediatric low-concentration suspension (0.03 mg/mL, i.e. 5 mL) under fasting conditions
Study NCT01489488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: Single oral dose of riociguat immediate release (IR) tablet 1 mg under fasting conditions
Study NCT01894191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation
Description: Insufflation during colonoscopy including insertion phase
Study NCT01894191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water immersion
Description: Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
Study NCT01894191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water exchange
Description: Water will infused and removed during insertion phase of colonoscopy
Study NCT01410032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plate fixation
Description: Reconstruction plate
Study NCT01410032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESIN
Description: ESIN (Elastic Stable Intramedullary Nailing)
Study NCT03364023 — intervention group
Intervention type: DEVICE
Intervention: Neurothrombectomy
Description: Medtronic Market-Released Neurothrombectomy Device
Study NCT03340701 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: vaginal progesterone suppository
Description: 200mg vaginal suppository micronized progesterone
Study NCT04669639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Block procedures for shoulder surgery analgesia
Description: The patients in group (a) will be placed in lateral decubitus. Then, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used to locate the transverse process of T2, where a needle will be inserted in a cephalocaudal direction until reaching the space between the fascia of the erector spinae and the transverse process of T2 and 30 ml of local anesthetic of bupivacaine 0.5% will be injected.~* In group (b), SSC nerve block will be done as follow: In the suprascapular notch, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used. The linear probe, enveloped in a sterile sheath, will be placed parallel to the spine of the scapula to visualize it and then will be moved cephalic to the supraspinatus fossa. The probe will then be moved laterally up to the scapular notch, where the nerve will be identified by its round hyperechogenic shape 4 cm deep.~* control group: patients will receive only general anesthesia
Study NCT04669639 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Block procedures for shoulder surgery analgesia
Description: The patients in group (a) will be placed in lateral decubitus. Then, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used to locate the transverse process of T2, where a needle will be inserted in a cephalocaudal direction until reaching the space between the fascia of the erector spinae and the transverse process of T2 and 30 ml of local anesthetic of bupivacaine 0.5% will be injected.~* In group (b), SSC nerve block will be done as follow: In the suprascapular notch, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used. The linear probe, enveloped in a sterile sheath, will be placed parallel to the spine of the scapula to visualize it and then will be moved cephalic to the supraspinatus fossa. The probe will then be moved laterally up to the scapular notch, where the nerve will be identified by its round hyperechogenic shape 4 cm deep.~* control group: patients will receive only general anesthesia
Study NCT06259266 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anti-reflux valve for dialysis catheter
Study NCT06259266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-reflux valve for dialysis catheter
Study NCT03920033 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Salvage radiation therapy
Description: Salvage radiation therapy for biochemical recurrence
Study NCT03920033 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Salvage radiation therapy
Description: Salvage radiation therapy for biochemical recurrence
Study NCT01651195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Study NCT01651195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Study NCT01651195 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01651195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00963196 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid
Description: 2400mg daily of fish oil containing 1440mg combined EPA and DHA for 12 weeks
Study NCT00963196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bovine gelatin capsules
Description: Bovine gelatin capsules that appear similar to active drug acting as placebo.
Study NCT02058550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based intervention
Description: Receive reminder phone call
Study NCT01816659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: 500 mg by mouth once daily, beginning the day after colonoscopy for one week, and then escalation to 1000 mg/day. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
Study NCT01275430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sherlock 3CG
Description: Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
Study NCT01275430 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blind Placement
Description: PICCs will be placed blindly, without the use of any tip location/positioning device.
Study NCT02114814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes self-management program for Hispanics and their families
Description: The intervention group received an 8-weekly culturally tailored diabetes self-management and family support education program delivered in Spanish
Study NCT02114814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health educational program for Hispanics and their families
Description: The attention control group received 8-weekly education program on general health information
Study NCT01140243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LCPUFA
Description: premature infant formula supplemented with LCPUFA
Study NCT01140243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LCPUFA
Description: premature infant formula supplemented with LCPUFA
Study NCT02546804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HOT SALT WATER
Description: 25ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
Study NCT02546804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POTASSIUM PERMANGANATE
Description: 10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
Study NCT02546804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CHLORHEXIDINE
Description: 10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
Study NCT04254471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL3810
Description: 5mgQD, 7.5mgQD, 10mgQD
Study NCT04254471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin + etoposide
Description: Carboplatin and etoposide are background treatment.
Study NCT04254471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin + etoposide
Description: Carboplatin and etoposide are background treatment.
Study NCT04254471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01437722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% SPL7013 Gel
Description: vaginal gel
Study NCT01437722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% SPL7013 Gel
Description: vaginal gel
Study NCT01437722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: vaginal gel
Study NCT02787668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet
Description: Participants will be randomized (20 per group) to the carbohydrate restricted diet (i.e., CHO \<10%; fat >65%, protein 25%) or a low fat diet (CHO 55%; fat 20%; protein 25%) for 8 weeks. Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
Study NCT02787668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control, low-fat diet
Description: Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
Study NCT01789723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fusilev
Description: Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.
Study NCT04388709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1A
Description: Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once
Study NCT01204853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxentan
Description: sitaxentan sodium 100 mg
Study NCT02222974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIR 561 CL
Study NCT02222974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01213745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Study NCT01213745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention
Study NCT01789723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folotyn
Description: A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.
Study NCT01421511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: * TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion~* TR-701 FA Tablets, 200 mg, orally once daily
Study NCT01421511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: * Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion~* Linezolid Tablets, 600 mg, orally every 12 hours
Study NCT01213745 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT02943928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngoscope and chest CT image
Description: First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis
Study NCT01384760 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: During the first 4 months, subjects will come for a counseling session weekly and then monthly for the following months. During each counseling session (15 to 20 minutes), the registered dietitian will review the seven-day food diaries and offer recommendations for controlling caloric intake. A varied balanced diet with an emphasis on fruit and vegetables, and low-fat and low calorific products in appropriate portions were encouraged. The registered dietitian will also review the daily activity log sheet to check the exercise adherence and progression set by exercise instructor. Subjects will be encouraged to do 30 minutes aerobic exercise two to three times a week.
Study NCT01384760 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Simple lifestyle advice
Description: Subjects in control group will receive simple lifestyle advice from a clinician at baseline and month 6. This will be a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects are encouraged to perform regular 30-minute exercise 2 to 3 times per week. This is to resemble routine clinical practice.
Study NCT02635945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-680
Study NCT02635945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00102726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB497115
Description: SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.
Study NCT00102726 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
Study NCT01411774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: All patients will receive 10 sessions of therapy over 8 weeks using the evidence-based CBT protocol in POTS (2004). Sessions 1-4 will be held twice weekly; sessions 5-10 will be held on a weekly basis. Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-10 involve E/RP exercises specific to each youth.
Study NCT01411774 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: All patients will receive 10 sessions of therapy over 8 weeks using the evidence-based CBT protocol in POTS (2004). Sessions 1-4 will be held twice weekly; sessions 5-10 will be held on a weekly basis. Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-10 involve E/RP exercises specific to each youth.
Study NCT01411774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Description: D-cycloserine will be encapsulated into 25mg with identical placebo capsules. Youth will take (1 or 2) DCS or identical placebo capsule 1 hour before sessions 4-10. A 0.7mg/kg dosage corresponds with dosages found to be effective in adult studies (50mg/estimated average adult weight of 70kg=.71mg/kg). Accordingly, doses for this study will be about 0.7mg/kg. Two dosing levels will be used based upon weight ranges to ensure comparable mg/kg levels: children weighing 25-45kg will be given a dosage of 25mg (\~0.56-1.0 mg/kg/day), and children ≥46kg will be given 50mg provided in two 25mg capsules (\~0.50-1.08mg/kg/day). Doses will be given 1 hour before therapy sessions 4-10.
Study NCT01411774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pill placebo
Description: The pill placebo will be identical to the active study medication in every respect (e.g., size, shape, number of capsules, etc.).
Study NCT03792581 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EV1000 and closed-loop system
Description: This system will recommend when patients need fluid or not and adjust vasopressor administration automatically
Study NCT03792581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EV1000 and closed-loop system
Description: This system will recommend when patients need fluid or not and adjust vasopressor administration automatically